Adriamycin is widely used in chemotherapy to treat various types of cancer, including breast cancer, bladder cancer, lung cancer, and certain forms of leukemia and lymphoma. It works by interfering with the DNA replication process in cancer cells, effectively inhibiting their growth and proliferation. The drug is often administered intravenously and is a key component in combination chemotherapy regimens. Due to its potent mechanism of action, it is particularly effective in aggressive cancers. However, its use is closely monitored because of potential side effects, such as cardiotoxicity, which can lead to heart damage. Adriamycin is also used in research settings to study cancer cell behavior and drug resistance mechanisms.